323 related articles for article (PubMed ID: 32593547)
1. Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up.
Burton BK; Longo N; Vockley J; Grange DK; Harding CO; Decker C; Li M; Lau K; Rosen O; Larimore K; Thomas J;
Mol Genet Metab; 2020 Aug; 130(4):239-246. PubMed ID: 32593547
[TBL] [Abstract][Full Text] [Related]
2. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).
Thomas J; Levy H; Amato S; Vockley J; Zori R; Dimmock D; Harding CO; Bilder DA; Weng HH; Olbertz J; Merilainen M; Jiang J; Larimore K; Gupta S; Gu Z; Northrup H;
Mol Genet Metab; 2018 May; 124(1):27-38. PubMed ID: 29653686
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study.
Longo N; Zori R; Wasserstein MP; Vockley J; Burton BK; Decker C; Li M; Lau K; Jiang J; Larimore K; Thomas JA
Orphanet J Rare Dis; 2018 Jul; 13(1):108. PubMed ID: 29973227
[TBL] [Abstract][Full Text] [Related]
4. Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.
Zori R; Thomas JA; Shur N; Rizzo WB; Decker C; Rosen O; Li M; Schweighardt B; Larimore K; Longo N
Mol Genet Metab; 2018 Nov; 125(3):217-227. PubMed ID: 30146451
[TBL] [Abstract][Full Text] [Related]
5. Two-year interim safety and efficacy of pegvaliase in Japanese adults with phenylketonuria.
Ishige M; Ito T; Hamazaki T; Kuwahara M; Lee L; Shintaku H
Mol Genet Metab; 2023 Nov; 140(3):107697. PubMed ID: 37717412
[TBL] [Abstract][Full Text] [Related]
6. Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial.
Harding CO; Amato RS; Stuy M; Longo N; Burton BK; Posner J; Weng HH; Merilainen M; Gu Z; Jiang J; Vockley J;
Mol Genet Metab; 2018 May; 124(1):20-26. PubMed ID: 29628378
[TBL] [Abstract][Full Text] [Related]
7. Pegvaliase for the treatment of phenylketonuria: Final results of a long-term phase 3 clinical trial program.
Harding CO; Longo N; Northrup H; Sacharow S; Singh R; Thomas JA; Vockley J; Zori RT; Bulloch Whitehall K; Lilienstein J; Lindstrom K; Levy DG; Jones S; Burton BK
Mol Genet Metab Rep; 2024 Jun; 39():101084. PubMed ID: 38694233
[TBL] [Abstract][Full Text] [Related]
8. Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria.
Zori R; Ahring K; Burton B; Pastores GM; Rutsch F; Jha A; Jurecki E; Rowell R; Harding C
Mol Genet Metab; 2019; 128(1-2):92-101. PubMed ID: 31439512
[TBL] [Abstract][Full Text] [Related]
9. Evaluating change in diet with pegvaliase treatment in adults with phenylketonuria: Analysis of phase 3 clinical trial data.
Rohr F; Burton B; Dee A; Harding CO; Lilienstein J; Lindstrom K; MacLeod E; Rose S; Singh R; van Calcar S; Whitehall K
Mol Genet Metab; 2024 Mar; 141(3):108122. PubMed ID: 38184920
[TBL] [Abstract][Full Text] [Related]
10. Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials.
Gupta S; Lau K; Harding CO; Shepherd G; Boyer R; Atkinson JP; Knight V; Olbertz J; Larimore K; Gu Z; Li M; Rosen O; Zoog SJ; Weng HH; Schweighardt B
EBioMedicine; 2018 Nov; 37():366-373. PubMed ID: 30366815
[TBL] [Abstract][Full Text] [Related]
11. Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses.
Aryal M; Lau K; Boyer R; Zhou H; Abend J; Gu K; Olbertz J; Gupta S; Zoog S; Larimore K
Mol Genet Metab; 2021 Nov; 134(3):235-242. PubMed ID: 34716085
[TBL] [Abstract][Full Text] [Related]
12. Pegvaliase: Immunological profile and recommendations for the clinical management of hypersensitivity reactions in patients with phenylketonuria treated with this enzyme substitution therapy.
Hausmann O; Daha M; Longo N; Knol E; Müller I; Northrup H; Brockow K
Mol Genet Metab; 2019; 128(1-2):84-91. PubMed ID: 31375398
[TBL] [Abstract][Full Text] [Related]
13. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial.
Longo N; Harding CO; Burton BK; Grange DK; Vockley J; Wasserstein M; Rice GM; Dorenbaum A; Neuenburg JK; Musson DG; Gu Z; Sile S
Lancet; 2014 Jul; 384(9937):37-44. PubMed ID: 24743000
[TBL] [Abstract][Full Text] [Related]
14. Long-term comparative effectiveness of pegvaliase versus medical nutrition therapy with and without sapropterin in adults with phenylketonuria.
Burton BK; Clague GE; Harding CO; Kucuksayrac E; Levy DG; Lindstrom K; Longo N; Maillot F; Muntau AC; Rutsch F; Zori RT
Mol Genet Metab; 2024 Jan; 141(1):108114. PubMed ID: 38142628
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria.
Qi Y; Patel G; Henshaw J; Gupta S; Olbertz J; Larimore K; Harding CO; Merilainen M; Zori R; Longo N; Burton BK; Li M; Gu Z; Zoog SJ; Weng HH; Schweighardt B
Clin Transl Sci; 2021 Sep; 14(5):1894-1905. PubMed ID: 34057292
[TBL] [Abstract][Full Text] [Related]
16. Pegvaliase: a novel treatment option for adults with phenylketonuria.
Mahan KC; Gandhi MA; Anand S
Curr Med Res Opin; 2019 Apr; 35(4):647-651. PubMed ID: 30247930
[TBL] [Abstract][Full Text] [Related]
17. Formulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuria.
Bell SM; Wendt DJ; Zhang Y; Taylor TW; Long S; Tsuruda L; Zhao B; Laipis P; Fitzpatrick PA
PLoS One; 2017; 12(3):e0173269. PubMed ID: 28282402
[TBL] [Abstract][Full Text] [Related]
18. Palynziq clinic: One year and 43 patients later.
Lah M; McPheron M
Mol Genet Metab; 2021 Jul; 133(3):250-256. PubMed ID: 34074593
[TBL] [Abstract][Full Text] [Related]
19. Pegvaliase therapy for phenylketonuria: Real-world case series and clinical insights.
Scala I; Brodosi L; Gueraldi D; Manti F; Rovelli V; Zuvadelli J; Agnelli G; Cazzorla C; Nardecchia F; Giammanco A; Biasucci G
Mol Genet Metab; 2024 May; 142(1):108151. PubMed ID: 38522180
[TBL] [Abstract][Full Text] [Related]
20. Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now?
Sarkissian CN; Gámez A
Mol Genet Metab; 2005 Dec; 86 Suppl 1():S22-6. PubMed ID: 16165390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
